Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

• Status: Completed
• Trial end date: 2019-11-29
• Target enrollment: 0
• Participant gender: All

Summary

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder in which a substantial number of patients cannot attain treatment target despite antidiabetic drugs. The renin-angiotensin system (RAS) has recently been implicated in the development of insulin resistance and impaired glucose metabolism. This study investigates the effect of adding RAS inhibitors to standard antidiabetic therapy in patients with T2DM. The primary outcome measure is the change in serum glycosylated hemoglobin A1c after 24 weeks of treatment. Secondary outcomes measures include changes in plasma lipid profile and blood pressure after treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nantou Christian Hospital
• Treatments: Metformin; Valsartan

Criteria

Inclusion Criteria:

• adults over 21 years of age

• clinically diagnosed type 2 diabetes mellitus

• recipients of metformin monotherapy

• compliance with prescriptions and dietary intervention

Exclusion Criteria:

• recipients of any second-line antidiabetic drug in addition to metformin

• recipients of any antihypertensive medication before study enrollment

• hemoglobin disorders

• chronic kidney disease

• thyroid dysfunction